Characterization of human colon cancer antigens recognized by autologous antibodies

International Journal of CancerVolume 76, Issue 5 p. 652-658 Human CancerFree Access Characterization of human colon cancer antigens recognized by autologous antibodies Matthew J. Scanlan, Corresponding Author Matthew J. Scanlan scanlanm@mskcc.org Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USALudwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Fax: (212)717-3100Search for more papers by this authorYao-Tseng Chen, Yao-Tseng Chen Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA Cornell University Medical College, New York, NY, USASearch for more papers by this authorBarbara Williamson, Barbara Williamson Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this authorAli O. Gure, Ali O. Gure Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this authorElisabeth Stockert, Elisabeth Stockert Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this authorJohn D. Gordan, John D. Gordan Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this authorÖzlem Türeci, Özlem Türeci Medizinische Klinik and Poliklinik, Innere Medizin I, University of Saarland Medical School, Homburg, GermanySearch for more papers by this authorUgur Sahin, Ugur Sahin Medizinische Klinik and Poliklinik, Innere Medizin I, University of Saarland Medical School, Homburg, GermanySearch for more papers by this authorMichael Pfreundschuh, Michael Pfreundschuh Medizinische Klinik and Poliklinik, Innere Medizin I, University of Saarland Medical School, Homburg, GermanySearch for more papers by this authorLloyd J. Old, Lloyd J. Old Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this author Matthew J. Scanlan, Corresponding Author Matthew J. Scanlan scanlanm@mskcc.org Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USALudwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Fax: (212)717-3100Search for more papers by this authorYao-Tseng Chen, Yao-Tseng Chen Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA Cornell University Medical College, New York, NY, USASearch for more papers by this authorBarbara Williamson, Barbara Williamson Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this authorAli O. Gure, Ali O. Gure Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this authorElisabeth Stockert, Elisabeth Stockert Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this authorJohn D. Gordan, John D. Gordan Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this authorÖzlem Türeci, Özlem Türeci Medizinische Klinik and Poliklinik, Innere Medizin I, University of Saarland Medical School, Homburg, GermanySearch for more papers by this authorUgur Sahin, Ugur Sahin Medizinische Klinik and Poliklinik, Innere Medizin I, University of Saarland Medical School, Homburg, GermanySearch for more papers by this authorMichael Pfreundschuh, Michael Pfreundschuh Medizinische Klinik and Poliklinik, Innere Medizin I, University of Saarland Medical School, Homburg, GermanySearch for more papers by this authorLloyd J. Old, Lloyd J. Old Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USASearch for more papers by this author First published: 06 December 1998 https://doi.org/10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.0.CO;2-PCitations: 237AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract The screening of cDNA expression libraries derived from human tumors with autologous antibody (SEREX) has proven to be a powerful method for defining the structure of tumor antigens recognized by the humoral immune system. In the present study, 48 distinct antigens (NY-CO-1–NY-CO-48) reactive with autologous IgG were identified by SEREX analysis in 4 patients with colon cancer. Sequencing analysis showed that 17 of the cDNA clones were previously uncharacterized molecules and 31 represented known gene products. The individual cDNA clones were analyzed in the following manner: a search for mutations or other structural changes; an analysis of mRNA expression in a panel of normal tissues; and a frequency analysis of the antibody response to the expressed product in the sera of colon cancer patients and normal individuals. The initial analysis showed NY-CO-13 to be a mutated version of the p53 tumor suppressor gene. Three of the 48 antigens showed a differential pattern of mRNA expression, with NY-CO-27 (galectin-4) expressed primarily in gastrointestinal tract, and NY-CO-37 and -38 showing a pattern of tissue-specific isoforms. With regard to immunogenicity, 20 of the 48 antigens were detected by allogeneic sera; 14 of these were reactive with sera from both normal donors and cancer patients, and 6 other clones (NY-CO-8, -9, -13, -16, -20 and -38) reacted exclusively with sera from colon cancer patients (ranging from 14% to 27%). Our results on colon cancer illustrate both the complexity and the potential of the SEREX approach for analysis of the humoral immune response against human cancer. Int. J. Cancer76:652–658, 1998.© 1998 Wiley-Liss, Inc. Citing Literature Volume76, Issue529 May 1998Pages 652-658 ReferencesRelatedInformation